From Research at med.fsu.edu Fri May 6 16:35:51 2022 From: Research at med.fsu.edu (med-Research) Date: Fri, 6 May 2022 20:35:51 +0000 Subject: Funding Opportunities Message-ID: Congressionally Directed Medical Research Programs: Open Funding Opportunities Autism Pre-applications due May 23. Bone Marrow Failure Pre-applications due June 29. Kidney Cancer Pre-applications due June 2 and June 23 (depending on the program). Lung Cancer Pre-applications due July 13. Multiple Sclerosis Pre-applications due June 23 and August 2 (depending on the program). Neurofibromatosis Pre-applications due June 30. Ovarian Cancer Pre-applications due June 22. Pancreatic Cancer Pre-applications due July 8. Peer Reviewed Alzheimer's Pre-applications due June 17. Peer Reviewed Cancer Pre-applications due May 25, July 12, and August 17 (depending on the program). Peer Reviewed Orthopaedic Pre-applications due June 16. Prostate Cancer Pre-applications due June 2, July 7, and August 4 (depending on the program). Rare Cancers Pre-applications due June 22 and July 18 (depending on the program). Spinal Cord Injury Pre-applications due May 23. Tick-Borne Disease Pre-applications due May 26. Tuberous Sclerosis Complex Pre-applications due June 30. Med-RA deadline to receive draft documents: 10 business days before submission to sponsor. When Everyone Survives Leukemia Research Foundation Grants Grants of $50,000 for one year are offered to new and established investigators who are requesting support for laboratory, translational, or clinical research related to acute leukemia. The WES Foundation is supports leukemia research because it recognizes that significant advances in the understanding, diagnosis, and treatment of leukemia are needed to achieve the goal of "When Everyone Survives". Due June 1. Med-RA deadline to receive draft documents: May 16 due to Memorial Day holiday. Genentech Corporate Giving: 2022 Health Equity & Diversity in STEM Innovation Fund The Health Equity and Diversity in STEM Innovation Fund invites proposals to support major priorities: 1. Health Equity: Increasing representation of communities of color in clinical research and eliminating inequities in care delivery Strong proposals will align with the following high-level outcomes: * Increase trust, engagement, and partnership between research institutions, hospitals/healthcare systems, and communities of color (including approaches that acknowledge and repair historic and ongoing harms inflicted upon communities of color) * Increase enrollment and retention of patients of color in clinical research by expanding access and embedding effective and purposeful engagement practices * Advance the science of how "the social becomes biological"-how structural racism (not "biological race") influences biological mechanisms-and the implications for clinical research and care delivery * Advance the knowledge of sustainable approaches to community-partnered care delivery (e.g., effective integration approaches, addressing cultural and operational differences between health care and human services organizations and mitigating unintended consequences) * Improve access to, persistence in, and satisfaction with specialty care for patients of color * Begin to close inequities in health care outcomes between racial and ethnic groups * Develop and strengthen accountability measures to promote antiracism, diversity, equity and inclusion across health care systems and research institutions 1. Workforce Diversity: Dismantling barriers to a diverse, inclusive and antiracist scientific and health care workforce Strong proposals will align with the following high-level outcomes: * Increase recruitment, retention, well-being and advancement of the next generation of diverse and antiracist scientific and medical talent * Develop and test cutting-edge approaches to scientific and medical training that center diversity, inclusion and antiracism * Catalyze new types of sustainable partnerships and collaborations across sectors (e.g., academia and industry) to build greater alignment, co-develop solutions and redirect funding flows that enable greater diversity in the scientific and health care workforce Due June 10. Med-RA deadline to receive draft documents: May 27th due to Memorial Day holiday. Michelson Prizes: Human Vaccines Project The Michelson Prizes: Next Generation Grants are $150,000 research grants given annually to support promising researchers who are applying disruptive concepts and inventive processes to advance human immunology, vaccine discovery, and immunotherapy research for major global diseases. The committee will be looking for research aimed at tackling the current roadblocks that exist in human vaccine development and expanding our limited understanding of key immune processes that are fundamental to successful vaccine and immunotherapy development. The Michelson Prizes are awarding research that is highly innovative and impactful, with the potential to be applied across many diseases. While the Michelson Prizes are focused on research in the fields of immunology, vaccine and immunotherapy discovery, applicants from the full spectrum of related disciplines, including clinical research, biochemistry, molecular biology, protein engineering, computer science, artificial intelligence/machine learning, biophysics, nanotechnology, etc., are encouraged to apply. Due June 26. Med-RA deadline to receive draft documents: June 13. National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders or Alcohol Use Disorder (U01 Clinical Trial Optional) The purpose of this Funding Opportunity Announcement (FOA) is to accelerate innovative drug and device therapies translation from discovery to early human studies. Studies appropriate for this FOA will develop pharmacologic and neuromodulatory tools for basic and clinical research on mental health disorders or alcohol use disorder (AUD); develop and validate tools (pharmacologic or neurostimulation) in support of experimental therapeutic studies of innovative candidates for mental disorders or AUD; and support early-stage human studies to rapidly assess the safety, tolerability, and pharmacodynamics of promising drug candidates/devices and new indications for novel Investigational New Drug (IND)-ready agents or Investigational Device Exemption (IDE)-ready devices for the treatment of mental disorders or AUD. This FOA encourages applications to advance the discovery, preclinical development, and proof of concept (PoC) testing of new, rationally based candidate agents and neurostimulation approaches to treat mental disorders or AUD, and to develop novel ligands and circuit-engagement devices as tools to further characterize existing or to validate new drug/device targets. This FOA will also support applications proposing preclinical discovery of biotechnology products and biologics with potential as candidate therapeutics including, but not limited to, large biologic macromolecules, (e.g., proteins, antibodies, and peptides), gene-based therapies (i.e., oligonucleotide- and viral vector-based), cell therapies, and novel emerging therapies (e.g., microbial and microbiome therapies). Due June 27, 2022; October 25, 2022; February 24, 2023; June 26, 2023; October 26, 2023; February 27, 2024; June 25, 2024; October 25, 2025; and February 24, 2025. Med-RA deadline to receive draft documents for June 2022 due date: June 14. TMCity Foundation: Investigating the Gut-Brain Axis for Applications to Brain and Mental Health This RFP seeks to address the gaps in our knowledge of how the gut affects brain health, with the goal of harnessing that knowledge to bring about measurable improvements to our prevention and treatment of neuropsychiatric diseases. In other words, our aim is to understand and improve brain health by advancing our understanding of the gut and its relationship to the brain. TMCity Foundation will make an expected 1-3 grants, up to $250,000. Due July 1. Med-RA deadline to receive draft documents: June 17. Alzheimer's Drug Discovery Foundation: Drug Development Program The Drug Development RFP seeks to support in vivo preclinical studies that advance lead molecules developed for Alzheimer's disease and related dementias to IND-enabling studies. The proposed studies should be structured to deliver a compound with strong potential for clinical and commercial application. This funding opportunity prioritizes novel drug mechanisms and modes of action related to the biology of aging and other emerging therapeutic areas for dementia. For this reason, amyloid targeted approaches and cholinesterase inhibitor proposals will not be considered for this RFP. Stage of discovery: * Preclinical pharmacokinetics (PK) and pharmacodynamics (PD) (primarily to inform dose selection for in vivo efficacy studies), as well as preliminary rodent tolerability studies * In vivo efficacy or proof-of-concept studies in animal models of disease or aging, with a focus on direct and indirect markers of target engagement and downstream pharmacologic effects * Please note: Applications that focus on basic research (including target discovery), assay development, and screening to identify hit compounds are not a priority for this RFP and will be withdrawn * Please note: IND-enabling work and clinical trials are supported through the Program to Accelerate Clinical Trials (PACT) RFP Therapeutic modalities: Includes small molecules, biologics, gene therapies, antisense oligonucleotides, and stem cells. Development of novel devices or delivery systems will not be considered for this RFP. Drug mechanisms or modes of action: Novel drug mechanisms and modes of action related to the biology of aging and other emerging therapeutic areas for dementia are considered high priority. These include, but are not limited to: * Epigenetics * Inflammation * Mitochondrial & metabolic function * Neuroprotection * Proteostasis * Synaptic activity and neurotransmitters * Vascular function * Other mechanisms and modes of action related to the biology of aging (e.g. senescent cells) * Other novel mechanisms or modes of action that are supported by compelling evidence demonstrating a rational biological connection to the disease process * Please note: Anti-amyloid approaches (e.g. anti-amyloid aggregation, beta-amyloid vaccines, beta- or gamma-secretase inhibitors) and cholinesterase inhibitor proposals will not be considered. Award Amount: Up to $600,000 based on stage and scope of research. No IDC. Award Duration: One year with potential for follow-on funding. Letter of intent due September 30, 2022. Med-RA deadline to receive draft documents: September 16. Alzheimer's Drug Discovery Foundation: Program to Accelerate Clinical Trials (PACT) The PACT RFP supports IND-enabling studies and early-phase clinical trials that test promising pharmacological interventions and devices for Alzheimer's disease (AD) and related dementias. Both disease-modifying and symptomatic agents will be considered. This funding opportunity prioritizes diverse drug mechanisms and modes of action related to the biology of aging and other emerging therapeutic areas for dementia. For this reason, amyloid targeted approaches and cholinesterase inhibitor proposals will not be considered for this RFP. Stage of development: 1. Early-stage human clinical trials including: * Phase 0 micro- or sub-therapeutic-dosing studies * Phase 1 trials in healthy subjects * Biomarker-based proof-of-concept studies (generally phase 1b or phase 2a trials) designed to assess target engagement and downstream pharmacologic effects 2. Regulatory studies including: * Non-GLP and GLP pharmacology and toxicology studies, pre-formulation, and GMP manufacture required for investigational new drug (IND) and clinical trial authorization (CTA) preclinical packages. Funding is available for preparation of traditional and exploratory IND applications * Long-term toxicology studies to enable longer-term dosing in phase 2 trials * GMP manufacturing and testing of clinical grade drug required to move into phase 2 or phase 3 trials For clinical trial applications, if IND-enabling work is in progress, funding for clinical studies would be contingent upon an IND (or equivalent) being granted and full review of the data package. Type of therapy: Novel, repurposed and repositioned drugs, as well as natural products and devices will be considered. Therapeutic modalities of interest include small molecules, peptides, antibodies, gene therapies, antisense oligonucleotides, and stem cells. Other non-pharmacologic interventions, such as diet, meditation, and exercise, will not be considered. Drug mechanisms or modes of action: Novel drug mechanisms and modes of action related to the biology of aging and other emerging therapeutic areas for dementia are considered high priority. These include, but are not limited to: * Epigenetics * Inflammation * Mitochondrial & metabolic function * Neuroprotection * Proteostasis * Synaptic activity and neurotransmitters * Vascular function * Other mechanisms and modes of action related to the biology of aging (e.g. senescent cells) * Other novel mechanisms or modes of action that are supported by compelling evidence demonstrating a rational biological connection to the disease process * Please note: Anti-amyloid approaches (e.g., anti-amyloid aggregation, beta-amyloid vaccines, beta- or gamma-secretase inhibitors) and cholinesterase inhibitor proposals will not be considered Average Duration: Varies Average Award: Up to $3 million; no IDC Letter of intent due September 30, 2022. Med-RA deadline to receive draft documents: September 19. Alzheimer's Drug Discovery Foundation: Prevention Beyond the Pipeline The ADDF seeks to support studies of cognitive symptoms due to health conditions, comparative effectiveness research, and epidemiological studies that probe whether the use or choice of drugs alters the risk for dementia or cognitive decline. The Prevention Pipeline RFP supports: 1. Studies of Cognitive Decline and Risk Reduction: Cognitive decline through aging and health conditions has been linked to an increased risk of dementia. The ADDF will consider funding programs to prevent and treat these conditions, including menopause-related cognitive symptoms, postoperative delirium and postoperative cognitive decline, mild and/or repetitive traumatic brain injury, and chemotherapy-induced decline. Methods may include epidemiology or clinical trials. For clinical trial proposals, please see below detailed instructions and priorities under "Expectations and Evaluation". 2. Comparative Effectiveness Research: For many health conditions, physicians have a choice of clinically equivalent drugs. Some of these drugs are being investigated for repurposing to treat Alzheimer's or related dementias, due to potential disease-modifying properties that go beyond the treatment of their approved disease indication. The ADDF will consider funding research to generate an evidence base on whether choices in the routine clinical care of pre-existing conditions could protect from dementia. Priority will be given to the comparison of drugs that are otherwise clinically equivalent for the pre-existing condition (see Box 1 in the ADDF 2016 position paper). Methods may include randomized trials or epidemiology. 3. Studies Leveraging the Consortium of Cohorts for Alzheimer's Prevention Action (CAPA): Epidemiological studies contribute unmatched information on whether the risk of dementia or cognitive decline may be influenced by long-term exposure to supplements or medications. However, high-powered studies are needed, ideally with dose, duration, and responder profiles, in order to translate epidemiological research into actionable interventions for testing. Through the CAPA Consortium, the ADDF funds collaborative analyses on dementia prevention using a minimum of five longitudinal cohorts, either harmonized or analyzed through parallel analysis of cohorts using a shared analysis script. More information here. Type of therapy: Novel, repurposed and repositioned drugs, as well as natural products and devices will be considered. Therapeutic modalities of interest include small molecules, peptides, antibodies, gene therapies, antisense oligonucleotides, and stem cells. Other non-pharmacologic interventions, such as diet, meditation, and exercise, will not be considered. Drug mechanisms or modes of action: Novel drug mechanisms and modes of action related to the biology of aging and other emerging therapeutic areas for dementia are considered high priority. These include, but are not limited to: * Epigenetics * Inflammation * Mitochondrial & metabolic function * Neuroprotection * Proteostasis * Synaptic activity and neurotransmitters * Vascular function * Other mechanisms and modes of action related to the biology of aging (e.g. senescent cells) * Other novel mechanisms or modes of action that are supported by compelling evidence demonstrating a rational biological connection to the disease process * Please note: Anti-amyloid approaches (e.g., anti-amyloid aggregation, beta-amyloid vaccines, beta- or gamma-secretase inhibitors) and cholinesterase inhibitor proposals will not be considered Grants of up to $3,000,000 will be awarded for clinical trials based on stage and scope of research. Letter of intent due September 30, 2022. Med-RA deadline to receive draft documents: September 19. Policy and Alzheimer's Disease (AD) and Alzheimer's Disease-Related Dementias (ADRD) Healthcare Disparities: Access, Utilization, and Quality (R01 Clinical Trial Not Allowed) This Funding Opportunity Announcement (FOA) solicits Research Project Grant (R01) applications for projects designed to exploit variations (e.g., geographic, temporal) in social and health care policies to employ experimental, quasi-experimental, or other innovative approaches to uncover mechanisms driving disparities in care (i.e., access, utilization, and quality) for persons living with Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD). Due October 20, 2022. Med-RA deadline to receive draft documents: October 10. Robert Wood Johnson Foundation: Pioneering Ideas-Culture of Health As our current reality underscores, we live in a dynamic world-where unforeseen global events; new technologies; scientific discoveries; changes in our climate, economy, demographics; and more-continually shape where and how we live, learn, work and play. These changes will profoundly impact health equity in our society, from our individual health and the health of our families to the health of our communities. What dramatic changes might we see in the next 5 to 15 years? What can we do today to create a better, more equitable tomorrow? We seek to answer these questions, anticipate the future, and support unconventional approaches and breakthrough ideas that can help lead the way to a future where everyone in the United States can live their healthiest life possible. Pioneering Ideas: Exploring the Future to Build a Culture of Health seeks proposals that are primed to influence health equity in the future. We are interested in ideas that address any of these four areas of focus: Future of Evidence; Future of Social Interaction; Future of Food; Future of Work. Additionally, we welcome ideas that might fall outside of these four focus areas, but which offer unique approaches to advancing health equity and our progress toward a Culture of Health. We want to hear from scientists, anthropologists, artists, urban planners, community leaders-anyone, anywhere who has a new or unconventional idea that could alter the trajectory of health, and improve health equity and well-being for generations to come. The changes we seek require diverse perspectives and cannot be accomplished by any one person, organization or sector. Proposals accepted on a rolling basis. Med-RA deadline to receive draft documents: 10 business days before submission to sponsor. -------------- next part -------------- An HTML attachment was scrubbed... URL: From Research at med.fsu.edu Mon May 23 14:18:35 2022 From: Research at med.fsu.edu (med-Research) Date: Mon, 23 May 2022 18:18:35 +0000 Subject: Request for Applications: 2022 CTSA Seed Grants Message-ID: Good Afternoon All, Toward meeting aims of the Clinical and Translational Science Award-to expand team science and translational research across FSU-the FSU Translational Health Steering Committee invites proposals for highly innovative, multidisciplinary pilot projects in two requests for applications: 1. Interventions that address chronic diseases in rural populations: Applications due June 23 2. Implementation science approaches to treating pain: Applications due June 30 Please see the attached RFAs for details. ~ COM Division of Research -------------- next part -------------- An HTML attachment was scrubbed... URL: -------------- next part -------------- A non-text attachment was scrubbed... Name: FSU_translational_health_pilot_chronic_diseases_2022.docx Type: application/vnd.openxmlformats-officedocument.wordprocessingml.document Size: 780066 bytes Desc: FSU_translational_health_pilot_chronic_diseases_2022.docx URL: -------------- next part -------------- A non-text attachment was scrubbed... Name: FSU_translational_health_pilot_RFA_pain_2022.docx Type: application/vnd.openxmlformats-officedocument.wordprocessingml.document Size: 783252 bytes Desc: FSU_translational_health_pilot_RFA_pain_2022.docx URL: From Research at med.fsu.edu Fri May 27 14:40:32 2022 From: Research at med.fsu.edu (med-Research) Date: Fri, 27 May 2022 18:40:32 +0000 Subject: Funding Opportunity Message-ID: HHMI is seeking creative and innovative early-career faculty for their new Freeman Hrabowski Scholars Program. They plan to fund 30 outstanding basic researchers, including physician-scientists, who have strong potential to become leaders in their fields and to advance diversity, equity, and inclusion through their mentorship and understanding of the experiences of trainees from races and ethnicities underrepresented in US science. Program Site: https://www.hhmi.org/programs/freeman-hrabowski-scholars Press Release https://www.hhmi.org/news/new-hhmi-program-pledges-1-5-billion-early-career-faculty-committed-diversity-equity-inclusion?utm_source=HHMI+News&utm_campaign=30ed733caa-FREEMAN_HRABOWSKI_SCHOLARS_2022_05_24&utm_medium=email&utm_term=0_8f2808e1d6-30ed733caa-69542865 Eligibility: The program is open to individuals who: * hold a PhD and/or MD (or equivalent) * began their first post-training position and a tenure-track (or equivalent) faculty position on or after July 1, 2018, or have accepted an offer for a tenure-track (or equivalent) position that will begin no later than July 1, 2023 * maintain a tenure-track appointment or equivalent at an eligible US institution; federal government employees are not eligible (FSU is an eligible institution) * have a research focus in any area of basic biomedical science, as well as plant biology, evolutionary biology, biophysics, chemical biology, biomedical engineering, and/or computational biology * are authorized to work in the US or can obtain work authorization for the duration of employment; HHMI sponsors visas for eligible individuals -------------- next part -------------- An HTML attachment was scrubbed... URL: